Biotechnology company Transgene (Euronext Paris:TNG) and NEC Corporation (NEC; TSE: 6701), a Japanese IT and electronics company, announced on Monday new data on TG4050, an individualized neoantigen cancer vaccine that demonstrates the ability to induce strong immune responses in patients.

TG4050 is based on Transgene's myvac platform, and the AI capabilities of NEC, and new positive data have been generated from patients with HPV-negative head and neck cancer and ovarian cancer, who have been enrolled in two ongoing Phase I trials assessing TG4050.

The vaccine shows promising immunogenicity and efficacy profiles and suggests the potential to extend the remission period for cancer patients who have undergone surgery, giving new hope to a patient population with no treatment options.

Transgene and NEC are preparing for a Phase II trial in head and neck cancers, which could be initiated in H2 2023. TG4050 has the potential to be developed for preventing relapses in other solid tumour indications.